KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $86.2 million.

  • Jazz Pharmaceuticals' Change in Accured Expenses rose 147.49% to $126.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 26.30%. This contributed to the annual value of $86.2 million for FY2024, which is 470.66% up from last year.
  • Jazz Pharmaceuticals' Change in Accured Expenses amounted to $86.2 million in FY2024, which was up 470.66% from -$23.2 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Change in Accured Expenses registered a high of $166.0 million during FY2022, and its lowest value of -$23.2 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $76.3 million, with a median of $86.2 million in 2024.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 1,528.16% in 2020, then plummeted by 114.00% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $79.5 million in 2020, then skyrocketed by 79.11% to $142.4 million in 2021, then rose by 16.60% to $166.0 million in 2022, then crashed by 114.00% to -$23.2 million in 2023, then skyrocketed by 470.66% to $86.2 million in 2024.